Royal Philips

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment businesses; Connected Care businesses; Personal Health businesses; and Other. The Diagnosis and Treatment businesses segment consists systems, smart devices, software and services, powered by AI-enabled informatics-that support precision diagnoses and minimally invasive procedures in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care businesses segment consists Hospital Patient Monitoring, Emergency Care, Sleep & Respiratory Care and Connected Care Informatics. The Personal Health businesses segment consists of Oral Healthcare, Personal Care,Mother and Child Care. The Other segment reports on the items Innovation & Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Koninklijke Philips NV is a technology company, which engages in the healthcare, lighting, and consumer well-being markets. It operates through the following segments: Diagnosis and Treatment; Connected Care; Personal Health; and Other. The Diagnosis and Treatment segment consists of systems, smart devices, software, and services, powered by AI-enabled solutions that support precision diagnoses and minimally invasive treatment in therapeutic areas such as cardiology, peripheral vascular, neurology, surgery, and oncology. The Connected Care segment focuses on Hospital Patient Monitoring, Sleep and Respiratory Care, and Enterprise Informatics. The Personal Health segment represents Oral Healthcare business unit, Personal Care business unit, and Mother and Child Care business unit. The Other segment is involved on the Innovation and Strategy, IP Royalties, Central costs, and other small items. The company was founded by Anton Frederik Philips and Gerard Leonard Frederik Philips in 1891 and is headquartered in Amsterdam, the Netherlands.

A massive recall of Philips breathing devices in 2021 due to a risk of potential injury has left physicians scrambling to find alternatives for the growing number of people who use them.

Explainer-What is the impact of Philips' recall of sleep apnea devices?

Philips to convene Extraordinary General Meeting of Shareholders to appoint Roy Jakobs as new President and Chief Executive Officer

The U.S. Food and Drug Administration (FDA) said reports of faulty Philips ventilators and sleep apnea machines had risen in the past quarter, underlining problems facing the Dutch company, which has just announced plans to replace its CEO.

FDA says faulty Philips device reports accelerating as CEO departs

Dutch health technology company Philips on Tuesday unexpectedly announced that Chief Executive Officer Frans van Houten would be replaced with company insider Roy Jakobs on October 15.

Philips says CEO Van Houten to leave in October

Philips announces CEO succession

Philips generates positive cash flows even during these turbulent times. Product recall and litigation will hang over the stock until 2023-24.

Philips: Doubling Down

Vascular experts establish Appropriate Use of Intravascular Ultrasound (IVUS) in peripheral interventions

Partnership inspires gamers to use Philips Norelco OneBlade to shape, shave and show up as their best selves STAMFORD, Conn. , Aug. 4, 2022 /PRNewswire/ -- Today, Philips, a global leader in health technology, announced a partnership with the premier voice of Esports, Scott Cole, to inspire gamers to look and feel their best.

Philips Norelco and Scott Cole, the Preeminent Voice of Esports, Partner to Help Esports Athletes Look and Feel Their Best

Koninklijke Philips' (PHG) Q2 top and bottom-line results reflect the negative impact of supply chain constraints and COVID lockdowns in China.

Philips' (PHG) Q2 Earnings Down on Supply Chain Constraints

Koninklijke Philips N.V. (NYSE:PHG ) Q2 2022 Results Conference Call July 25, 2022 4:00 AM ET Company Participants Leandro Mazzoni - Head, IR Frans van Houten - CEO Abhijit Bhattacharya - CFO Roy Jakobs - Chief Business Leader, Connected Care Francis Kim - Chief Quality and Regulatory Officer Conference Call Participants Hassan Al-Wakeel - Barclays David Adlington - JPMorgan Cazenove Julien Dormois - Exane BNP Paribas Graham Doyle - UBS James Vane-Tempest - Jefferies Falko Friedrichs - Deutsche Bank Ed Ridley-Day - Redburn Delphine Le Louet - Societe Generale Leandro Mazzoni Hi, everyone.

Koninklijke Philips N.V. (PHG) CEO Frans van Houten on Q2 2022 Results - Earnings Call Transcript

The company says it expects full-year sales growth of 1% to 3%, down from its previous forecast of 3% to 5%.

Philips Stock Sinks on Cut to Sales Guidance

Royal Philips NV PHG, -0.05% PHIA, -9.54% on Monday reported a swing to a net loss for the second quarter, which it blamed on a number of issues including pandemic-related lockdowns in China, inflationary pressures and the Russia-Ukraine war.

Philips swings to loss and cuts sales guidance

Dutch medical equipment maker Philips on Monday reported a worse-than-expected drop in second-quarter core earnings to 216 million euros ($220 million), citing supply shortages and lockdowns in China.

Philips misses Q2 forecasts, cites supply chain issues and China lockdowns

Philips' performance impacted by headwinds; order book strength and improving component supplies expected to deliver growth and profitability improvement from second half of 2022 onwards

Koninklijke Philips (PHG) announces that its latest AI-powered MR acceleration software SmartSpeed will be showcased as part of the AI-powered precision diagnosis portfolio at ECR.

Philips (PHG) Expands AI Portfolio With SmartSpeed Solution

July 13, 2022  Philips demonstrates portfolio of smart connected imaging systems and integrated radiology workflow solutions designed to improve diagnostic confidence and clinical outcomes Amsterdam, the Netherlands and Vienna, Austria – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its award-winning AI-powered systems and solutions debuting at the European Congress of Radiology (ECR, July 13-17, Vienna, Austria).  Philips will demonstrate how its portfolio of smart connected imaging systems and integrated radiology workflow solutions help increase diagnostic confidence and clinical outcomes; help reduce staff stress and burnout; improve patient engagement and quality access to care; and enhance efficiency to help reduce waste. “Radiology plays such a critical role in diagnosing and guiding patients into the right treatment plans. That's why we designed our smart connected imaging systems to deliver first time right diagnoses with the latest clinical technologies and applications to drive patient-centric insights supporting early and definitive diagnosis and treatment,” said Kees Wesdorp , Chief Business Leader of Precision Diagnosis at Philips. “Addressing operational inefficiencies across the entire radiology enterprise was also the driving force behind the introduction of our AI-enabled, software defined systems and solutions to assist customers by automating and accelerating routine tasks, generating insights from large amounts of data to help improve productivity and lower the risk of staff burnout.” Smart connected imaging systems help increase diagnostic confidence It is projected the amount of healthcare data will grow 36% each year by 2025 [1]. In the recent Future Health Index 2022 Global report commissioned by Philips, one of the biggest challenges facing radiology leaders is managing the sheer volume of data available to them, with nearly a quarter (24%) of those surveyed, citing data management as their top issue. Philips AI-powered leading technologies help turn relevant data into actionable insights to increase diagnostic confidence and improve clinical outcomes. New at ECR 2022, Philips will spotlight its latest AI-powered, software-defined MR smart systems, including its SmartSpeed artificial intelligence (AI) powered MR acceleration software , which delivers higher image resolution with 3 times faster scan times [2] and virtually no loss in image quality, representing a major step forward in diagnostic confidence and MR department productivity. Philips SmartSpeed joins the growing number of Philips AI powered workflow innovations available across the portfolio of smart Philips MR systems that will be showcased at ECR, including the European introduction of the new smart connected 3T MR system, Philips MR 7700 and the company's latest MR 5300 1.5T helium-free in operations MR system. Each of these systems uses intelligent software to automate tasks and help relieve the burden on busy radiology staff and departments. Also new to the European market and being showcased at ECR 2022 is the award-winning Philips Spectral CT 7500 , the latest intelligent system to deliver high quality spectral images for every patient on every scan 100% of the time to help improve disease characterization, and reduce rescans and follow-ups, all at the same dose levels as conventional scans. The time-saving spectral workflow is fully integrated, enabling the technologist to get the patient on and off the table quickly – spectral chest scans and head scans take less than one second, and a full upper body spectral scan can be completed in less than two seconds. The new Spectral CT 7500 has demonstrated a 34% reduction in time to diagnosis, a 25% reduction in repeat scans and a 30% reduction in follow-up scans [3]. Integrated radiology workflows drive operational efficiency and improve patient experience Operational inefficiencies continue to weigh heavily on clinicians and health systems as they strive to deliver the very best care for their patients. It is no surprise that 45% of radiologists reported symptoms of burnout pre-pandemic [4], while 97% of technologists report moderate or severe levels of job stress [5]. Visitors to the Philips Zone at ECR 2022 will see how Philips' end-to-end, vendor neutral solutions simplify and connect workflows to address productivity challenges across the radiology enterprise.  Philips Radiology Workflow Suite  is a combination of solutions that support clear and efficient radiology workflows. At ECR, Philips continues to expand its Radiology Workflow Suite, introducing new and enhanced solutions across the entire radiology workflow with a focus on:

Philips highlights AI-powered precision diagnosis portfolio at ECR 2022

Philips spotlights latest AI-powered, software-defined MR smart systems at ECR 2022

July 4, 2022 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 8,758,455 of its shares. The cancelled shares were acquired as part of the EUR 1.5 billion share repurchase program for capital reduction purposes that was announced on July 26, 2021. Philips' current issued share capital amounts to EUR 177,863,016.40 representing 889,315,082 common shares. As communicated earlier , Philips intends to have 19,571,218 shares delivered through the early settlement of forward contracts (entered into as part of the same share repurchase program) and to cancel those as well, which would result in 869,743,864 issued common shares at year-end 2022 (2021: 883,898,969). More information is available here .  For further information, please contact: Ben ZwirsPhilips Global Press OfficeTel.: +31 6 15213446E-mail: ben.zwirs@philips.com Derya GuzelPhilips Investor RelationsTel.: +31 20 59 77055E-mail: derya.guzel@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter . Forward-looking statements This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips' organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

Philips completes cancellation of 8.8 million shares

June 30, 2022 Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment   Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix , Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, to incorporate the results of Biodesix's Nodify Lung ® blood-based lung nodule risk assessment testing into Philips Lung Cancer Orchestrator lung cancer patient management system. The incorporation of proteomics data – along with the radiologic and patient history data currently used to determine treatment decisions – can help create diagnostic efficiency for cancer care centers in the management of a growing number of lung nodule cases, via the contextual launch of Biodesix Nodify Lung application within Lung Cancer Orchestrator. Philips Lung Cancer Orchestrator solution is designed to enable health systems to operationalize lung cancer screening and lung nodule management programs at scale. Lung cancer remains the leading cause of cancer deaths worldwide [1], with current 5-year survival rates after diagnosis typically less than 20% [2]. If detected and treated early, however, research shows 10-year survival rates could increase to more than 90% [3]. Thanks to the adoption of low-dose CT (computer tomography) screening and better management of incidental lung nodule findings, early-stage diagnosis and treatment is now possible, but has resulted in rapidly increasing caseloads. For example, recent changes in U.S. guidelines have nearly doubled the number of people now eligible for lung cancer screening [4]. “By incorporating Biodesix's Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, General Manager Oncology Informatics and Genomics at Philips. “We expect the inclusion of Biodesix's ground-breaking technology in Philips Lung Cancer Orchestrator to help drive more confident decisions for the care team, and ultimately benefit patients.” As a next-step after radiologic lung nodule assessment, minimally-invasive biopsy procedures such as endobronchial biopsy (accessing a nodule via the patient's airways), are already helping early-stage diagnosis. With 62% of biopsies conducted on benign nodules [5], by detecting the presence of blood-based biomarkers combined with clinical and radiomic factors, Biodesix's Nodify Lung blood-based proteomic tests help clinicians to reclassify the risk of malignancy to better target resources to those who need them. If a nodule is malignant, the delay in surgical care for cancer patients by four weeks increases the mortality by 6-8% [6]. “We are delighted that our tests are being incorporated into Philips' vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, Chief Executive Officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.” Philips Lung Cancer Orchestrator is an integrated patient management system for CT lung cancer screening programs and incidental lung nodule findings that keeps track of patients, appointments, diagnostic images, test results, and clinical decisions for every step of a lung cancer patient's screening and treatment journey. Fitting seamlessly into conventional screening and diagnostic workflows, it coordinates the end-to-end patient journey to create a fully traceable, fully documented timeline of scheduled actions, and aggregates data on tumor staging, radiology, pathology, and biomarker analyses for informed decision-making. The ability to order and receive the results expedites Biodesix's proteomic testing directly to and from the Lung Cancer Orchestrator at the same time it adds new insights on nodule risk of malignancy to further support the decision-making process. Lung Cancer Orchestrator is part of Philips' expanding portfolio of integrated cancer care solutions that seamlessly connect data, technology, operations, and clinical workflows to enable pivotal decision-making. Visit Philips Oncology to learn how Philips combines smart diagnostic and imaging technologies with connected workflows that integrate patient data from disparate systems, to provide solutions that put expert information at clinicians' fingertips to help expand the quality and reach of personalized cancer care. [1] International Agency for Research on Cancer, World Health Organization. Press Release N° 263. Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. 12 September 2018[2] https://www.medicinenet.com/what_is_the_most_survivable_cancer/article.htm [3] International Early Lung Cancer Action Program Investigators. Survival of patients with stage 1 lung cancer detected on CT screening. N Engl J Med. 2006;355:1763- 1771 DOI: 10.1056/NEJMoa060476.[4] Lane E, et al. Nearly twice as many people are now eligible for lung cancer screenings—here is what you need to know. Advisory Board publication. 2021.Washington, DC. https://www.advisory.com/sponsored/lung-cancer [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665735/ [6] Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ 2020;371:m4087 http://dx.doi.org/10.1136/bmj.m4087 For further information, please contact: Kathy O'ReillyPhilips Global Press OfficeTel.: +1 978-221-8919E-mail: kathy.oreilly@philips.com Twitter: @kathyoreilly About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter . About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com.

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

Philips provides update on Philips Respironics' PE-PUR sound abatement foam test and research program

Team OneBlade highlights Philips Norelco OneBlade, the innovative tool that can trim, edge and shave any length of hair so guys look and feel their best STAMFORD, Conn. , June 21, 2022 /PRNewswire/ -- Philips Norelco knows that draft night is among the biggest moments of any top professional basketball prospect's athletic career.

Philips drafts top prospects Paolo Banchero, Jaden Hardy, Chet Holmgren, and Jalen Williams to "Team OneBlade," an exclusive roster of players who look and feel their best on and off the basketball court

Philips awarded top honor by Red Dot jury with Design Team of the Year award

Philips to repurchase up to 3.2 million shares to cover long-term incentive and employee stock purchase plans

Philips announces positive three-year clinical research results from its Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial

In this article, we'll take a look at perhaps one of the most well-known conglomerates on Earth, Philips, with the original name Koninklijke Philips N.V. The company has a 100-year history, and has had some issues in the past few decades.

Philips: Upside From A Massive Conglomerate

News for Royal Philips Stock (PHG)